Innovent Initiates Pivotal Study for IBI363 in Advanced Colorectal Cancer

On August 5, 2026, Innovent Biologics, a leading Chinese biopharmaceutical company, announced the dosing of the first patient in a pivotal clinical study for IBI363 (also known as TAK-928), a groundbreaking potential treatment for advanced colorectal cancer (CRC). This exciting development was made in collaboration with Takeda, a global biopharmaceutical company renowned for its innovative therapies in oncology and other fields.

IBI363 is designed as a PD-1/IL-2α-biased bispecific fusion protein that aims to specifically target and treat what are termed 'cold' tumors, which are notoriously resistant to standard therapies, including checkpoint inhibitors. This particular study represents the third pivotal clinical trial initiated for IBI363, highlighting its critical role in the ongoing fight against advanced CRC, which has proven frustratingly difficult to treat, especially in cases that have already failed multiple lines of therapy.

The study will compare the effectiveness of IBI363 combined with bevacizumab against other therapy options chosen by investigators. A total of 550 patients who have shown refractory response or intolerance to standard therapies are set to be enrolled in this multi-center, open-label trial under clinical trial identifier NCT07722494. The main focus of this trial is to evaluate overall survival rates among participants, providing some hope for patients who are currently limited to poor treatment options.

Innovent has previously reported promising data regarding IBI363's efficacy when used in conjunction with bevacizumab. During the 2025 ASCO Annual Meeting, results from a Phase 1 clinical study showcased an overall confirmed objective response rate of 15.1% among patients treated with this combination, alongside a disease control rate of 61.6%. Notably, the average duration before disease progression reached 4.7 months. These early signs of efficacy have culminated in the drug being granted Breakthrough Therapy Designation by the National Medical Products Administration (NMPA) in China in May 2026, further signaling its promise as a new therapy for advanced microsatellite stable (MSS) or mismatch repair proficient (pMMR) colorectal cancer patients.

Professor Kefeng Ding, the principal investigator from the Second Affiliated Hospital of Zhejiang University, remarked on the pressing need for effective treatments addressing CRC, particularly as most cases are declared as 'immune-desert' or immune-suppressed. He noted the significance of IBI363’s dual action mechanism, which seeks to invigorate the immune response within these challenging tumors.

Dr. Hui Zhou, Chief R&D Officer for Oncology at Innovent, emphasized that IBI363 serves as a potential advancement in next-generation immunotherapy, potentially outstripping existing treatments aimed at these malignancies. The prospects of IBI363 are heightened by its unique development strategy, which combines the dual functionalities of both blocking PD-1 and stimulating tumor-specific T cells.

With IBI363 currently undergoing pivotal clinical trials in multiple conditions—including melanoma and NSCLC—its global potential is recognized. Innovent's collaboration with Takeda is crucial, allowing the duo to co-develop and realize shared commercialization of IBI363, especially in the U.S., with Takeda holding the reins elsewhere.

In summary, the ongoing effort to combat advanced colorectal cancer through innovative biopharmaceutical solutions like IBI363 promises hope for patients facing limited options. As further data emerges from these pivotal studies, there is cautious optimism surrounding IBI363's ability to offer a novel approach against this formidable disease.